Overview

To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment

Status:
RECRUITING
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial, aiming to evaluate the efficacy and safety of GST-HG141 in patients with chronic hepatitis B who have an inadequate response to antiviral drug treatment.
Phase:
PHASE3
Details
Lead Sponsor:
Fujian Akeylink Biotechnology Co., Ltd.